Produção Nacional
Revisado por pares
Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)
2018; Elsevier BV; Volume: 277; Linguagem: Inglês
10.1016/j.atherosclerosis.2018.08.051
ISSN1879-1484
AutoresAntonio J. Vallejo‐Vaz, Martina De Marco, C. Stevens, Asif Akram, Tomáš Freiberger, G. Kees Hovingh, John J.P. Kastelein, Pedro Mata, Frederick J. Raal, Raúl D. Santos, Handrean Soran, Gerald F. Watts, Marianne Abifadel, Carlos A. Aguilar‐Salinas, Mutaz Al-Khnifsawi, Fahad Alkindi, Fahad Alnouri, Rodrigo Alonso, Khalid Al‐Rasadi, Ahmad Al‐Sarraf, Tester F. Ashavaid, Christoph J. Binder, Martin P. Bogsrud, Mafalda Bourbon, Éric Bruckert, Krzysztof Chlebus, Pablo Corral, Olivier Descamps, Ronen Durst, М. В. Ежов, Zlatko Fras, Jacques Genest, Urh Grošelj, Mariko Harada‐Shiba, Meral Kayıkçıoğlu, Katarina Lalić, Carolyn S.P. Lam, Gustavs Latkovskis, Ulrich Laufs, Evangelos Liberopoulos, Jie Lin, Vincent Maher, Nelson Majano, Adéle Marais, Winfried März, Erkin М Мirrakhimov, André R. Miserez, Olena Mitchenko, Hapizah Nawawi, Børge G. Nordestgaard, György Paragh, Žaneta Petrulionienė, Belma Pojskić, Arman Postadzhiyan, Ashraf Reda, Željko Reiner, Wilson E. Sadoh, Amirhossein Sahebkar, Abdullah Shehab, Aleksander B. Shek, Mario Stoll, Ta‐Chen Su, Subramaniam Tavintharan, Andrey V. Susekov, Phivos Symeonides, Myra Tilney, Brian Tomlinson, Thanh‐Huong Truong, Alexandros D. Tselepis, Anne Tybjærg‐Hansen, Alejandra Vázquez-Cárdenas, Margus Viigimaa, Branislav Vohnout, Elisabeth Widén, Shizuya Yamashita, Maciej Banach, Dan Gaiţă, Lixin Jiang, Lennart Nilsson, Lourdes Ella G. Santos, Heribert Schunkert, Lâle Tokgözoğlu, Josip Car, Alberico L. Catapano, Kausik K. Ray,
Tópico(s)Health and Medical Research Impacts
ResumoBackground and aimsManagement of familial hypercholesterolaemia (FH) may vary across different settings due to factors related to population characteristics, practice, resources and/or policies. We conducted a survey among the worldwide network of EAS FHSC Lead Investigators to provide an overview of FH status in different countries.MethodsLead Investigators from countries formally involved in the EAS FHSC by mid-May 2018 were invited to provide a brief report on FH status in their countries, including available information, programmes, initiatives, and management.Results63 countries provided reports. Data on FH prevalence are lacking in most countries. Where available, data tend to align with recent estimates, suggesting a higher frequency than that traditionally considered. Low rates of FH detection are reported across all regions. National registries and education programmes to improve FH awareness/knowledge are a recognised priority, but funding is often lacking. In most countries, diagnosis primarily relies on the Dutch Lipid Clinics Network criteria. Although available in many countries, genetic testing is not widely implemented (frequent cost issues). There are only a few national official government programmes for FH. Under-treatment is an issue. FH therapy is not universally reimbursed. PCSK9-inhibitors are available in ∼2/3 countries. Lipoprotein-apheresis is offered in ∼60% countries, although access is limited.ConclusionsFH is a recognised public health concern. Management varies widely across countries, with overall suboptimal identification and under-treatment. Efforts and initiatives to improve FH knowledge and management are underway, including development of national registries, but support, particularly from health authorities, and better funding are greatly needed.
Referência(s)